NR4A1 and ductal breast carcinoma in situ: Since tamoxifen therapy became the standard of care treatment for hormone receptor-positive breast cancer and hormone receptor-positive DCIS, several studies have been conducted to investigate the neoplastic adverse events associated with tamoxifen use.